Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22288125 | 0.81 | MAPT (0.54) | MAPTKDM4ESMN1; SMN2CYP3A4HSP90AA1 | |
| SCHEMBL29661833 | 0.81 | MAPT (0.54) | MAPTKDM4ESMN1; SMN2CYP3A4HSP90AA1 | |
| SCHEMBL25536192 | 0.80 | MAPT (0.52) | MAPTKDM4ESMN1; SMN2CYP3A4HSP90AA1 | |
| SCHEMBL8834947 | 0.80 | MAPT (0.59) | MAPTKDM4ESMN1; SMN2CYP3A4HSP90AA1 | |
| SCHEMBL15700707 | 0.77 | MAPT (0.52) | MAPTKDM4ESMN1; SMN2CYP3A4HSP90AA1 | |
| SCHEMBL826577 | 0.76 | MAPT (0.62) | MAPTKDM4ESMN1; SMN2CYP3A4HSP90AA1 | |
| SCHEMBL25247480 | 0.76 | MAPT (0.47) | MAPTKDM4ESMN1; SMN2CYP3A4HSP90AA1 | |
| SCHEMBL8835421 | 0.74 | POLB (0.50) | MAPTKDM4ESMN1; SMN2CYP3A4L3MBTL1 | |
| SCHEMBL5547970 | 0.73 | MAPT (0.58) | MAPTKDM4ESMN1; SMN2CYP3A4HSP90AA1 | |
| SCHEMBL23596998 | 0.73 | MAPT (0.58) | MAPTKDM4ESMN1; SMN2CYP3A4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | MAPT 4854/4885KDM4E 3184/4885SMN1; SMN2 3645/4885 |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NME1, ADORA2A, GPR68 | MAPT 4854/4885KDM4E 3184/4885SMN1; SMN2 3645/4885 |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | MAPT 4854/4885KDM4E 3184/4885SMN1; SMN2 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.